There are currently 10 clinical trials in North Canton, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Neuro-Behavioral Clinical Research, Inc. and Neuro-Behavioral Clinical Research. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
03/25/2024
Locations: Neuro-Behavioral Clinical Research, Inc., North Canton, Ohio
Conditions: Pediatric Migraine
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Recruiting
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old. The study will be held in Approximately 50 global study centers and approximately 15 additional centers for a separate Japan population. Participation in the study can be up to approximately 12 weeks.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: Dr. Shishuka Malhotra, North Canton, Ohio
Conditions: Generalized Anxiety Disorder
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
Recruiting
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Neuro-Behaviroral Clinical Research, Inc., North Canton, Ohio
Conditions: Treatment Resistant Depression
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (10 mg QD and 30 mg QD) in male and female participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: North Canton, Ohio, North Canton, Ohio
Conditions: Schizophrenia
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Recruiting
The primary purpose of this study is to assess the long-term safety and tolerability of oral emraclidine in adult participants with schizophrenia.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/12/2024
Locations: North Canton, Ohio, North Canton, Ohio
Conditions: Schizophrenia
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives o... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: Neuro-Behavioral Clinical Research, North Canton, Ohio
Conditions: Schizophrenia
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
Recruiting
The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (including mild cognitive impairment [MCI] and mild dementia due to AD) of 2 dose levels of GSK4527226 compared to placebo.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/12/2024
Locations: GSK Investigational Site, North Canton, Ohio
Conditions: Alzheimer's Disease
A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)
Recruiting
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive impairment (MCI) or mild-to-moderate Alzheimer's Disease (AD). The primary hypothesis (Part 1) is that at a generally well tolerated dose level, the true geometric mean concentration at Day 85 of MK-2214 in cerebrospinal fluid is >0.3 nanomolar (nM). Optional healthy older participants (Part 2) may receive MK-2214 at dose levels determined by criter... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/03/2024
Locations: Neuro-Behavioral Clinical Research ( Site 0016), North Canton, Ohio
Conditions: Alzheimer Disease
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
Recruiting
This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to placebo to improve the amount of hemoglobin in the blood and to reduce the number of vaso-occlusive crises (times when the blood vessels become blocked and cause pain).
Gender:
All
Ages:
Between 12 years and 65 years
Trial Updated:
11/05/2023
Locations: Neuro-Behavioral Clinical Research, North Canton, Ohio
Conditions: Sickle Cell Disease
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
Recruiting
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, multi-arm, multi-stage inpatient study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of NBI-1117568 compared with placebo in adult subjects with a primary diagnosis of schizophrenia, who are experiencing an acute exacerbation or relapse of symptoms.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
09/15/2023
Locations: Neurocrine Clinical Site, North Canton, Ohio
Conditions: Schizophrenia